Determination of the Underlying Cause of Death in Three Multicenter International HIV Clinical Trials
- 1 June 2008
- journal article
- research article
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 9 (3) , 177-185
- https://doi.org/10.1310/hct0903-177
Abstract
Purpose: Describe processes and challenges for an Endpoint Review Committee (ERC) in determining and adjudicating underlying causes of death in HIV clinical trials. Method: Three randomized HIV trials (two evaluating interleukin-2 and one treatment interruption) enrolled 11,593 persons from 36 countries during 1999–2008. Three ERC members independently reviewed each death report and supporting source documentation to assign underlying cause of death; differences of opinion were adjudicated. Results: Of 453 deaths reported through January 14, 2008, underlying causes were as follows: 10% AIDS-defining diseases, 21% non-AIDS malignancies, 9% cardiac diseases, 9% liver disease, 8% non-AIDS-defining infections, 5% suicides, 5% other traumatic events/accidents, 4% drug overdoses/acute intoxications, 11% other causes, and 18% unknown. Major reasons for unknown classification were inadequate clinical information or supporting documentation to determine cause of death. Half (51%) of deaths reviewed by the ERC required follow-up adjudication; consensus was eventually always reached. Conclusion: ERCs can successfully provide blinded, independent, and systematic determinations of underlying cause of death in HIV clinical trials. Committees should include those familiar with AIDS and non-AIDS-defining diseases and have processes for adjudicating differences of opinion. Training for local investigators and procedure manuals should emphasize obtaining maximum possible documentation and follow-up information on all trial deaths.Keywords
This publication has 53 references indexed in Scilit:
- Increase in Non-AIDS Related Conditions as Causes of Death among HIV-Infected Individuals in the HAART Era in BrazilPLOS ONE, 2008
- Class of Antiretroviral Drugs and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2007
- Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural UgandaAIDS, 2007
- Value of an Endpoints Committee versus the use of nosologists for validating cause of deathContemporary Clinical Trials, 2006
- Thoughts of Death and Suicidal Ideation in Nonpsychiatric Human Immunodeficiency Virus Seropositive IndividualsDeath Studies, 2006
- Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDSInternational Journal of Epidemiology, 2004
- Changes in Mortality Related to Human Immunodeficiency Virus Infection: Comparative Analysis of Inpatient Deaths in 1995 and in 1999–2000Clinical Infectious Diseases, 2003
- Trends in Causes of Death among Persons with Acquired Immunodeficiency Syndrome in the Era of Highly Active Antiretroviral Therapy, San Francisco, 1994–1998The Journal of Infectious Diseases, 2002
- Management of Psychiatric Disorders in Patients Infected with Human Immunodeficiency VirusClinical Infectious Diseases, 2001
- Bacterial Pneumonia in Persons Infected with the Human Immunodeficiency VirusNew England Journal of Medicine, 1995